# Armetheon

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/armetheon

- Industry: Pharmaceuticals
- Headquarters: Menlo Park, US
- Website: www.armetheon.com
- Total disclosed funding: $31M
- Latest round: Series B (Jan 21, 2015)
- Investors on record: 7

## About

Armetheon, Inc. is a biotechnology company focused on developing and commercializing advanced therapeutic solutions to address unmet medical needs in the healthcare sector.Founded in 2011 and headquartered in Menlo Park, US, Armetheon, Inc. specializes in innovative medical treatments. In Q2 2017, the company merged with Espero Pharmaceuticals, Inc. to form Espero BioPharma, Inc. The latest funding round was a Series B, raising USD 24.35 mn from multiple investors including Amkey Ventures and CDIB Capital Group, bringing the total amount raised to USD 24.35 mn and the current company valuation to USD 131.45 mn.Armetheon, Inc. specializes in the development and commercialization of innovative therapeutic solutions, primarily focusing on advanced medical treatments. The company’s core product offerings include proprietary technologies designed to address unmet medical needs in various therapeutic areas. Their primary aim is to improve patient outcomes by providing solutions that enhance the efficacy and safety of treatments, which are intended for use in both hospital settings and outpatient care facilities. The company serves a diverse clientele across several geographical markets, including North America, Europe, and parts of Asia.The revenue structure of Armetheon, Inc. is primarily driven by direct sales of its advanced therapeutic products and potential partnerships with healthcare providers and institutions. Transactions typically occur through B2B arrangements, where hospitals and clinics procure their products to enhance treatment options for patients. The company may also engage in subscription models for ongoing access to proprietary technologies or services, with flagship offerings forming a significant part of the revenue generation strategy.Armetheon, Inc. plans to utilize the funding raised in the Series B round to enhance its research and development efforts. The company aims to introduce new therapeutic products, although specific launch dates are not disclosed. In addition, Armetheon is targeting expansions into new geographical markets to increase its reach. The merger with Espero Pharmaceuticals, Inc. in 2017 is expected to bolster its capabilities and product offerings. Through these initiatives, the company intends to strengthen its position within the healthcare market.

## Funding rounds

- Series B, Jan 21, 2015, $24M — CDIB Capital Group, Amkey Ventures, iD SoftCapital, Hercules Bioventures, Capital TEN II
- Series A, Aug 28, 2014, $7M — Atheneos Ventures, Hercules Bioventures, AshHill Biomedical Investments

## Investors

- Atheneos Ventures (https://capitalatlas.ai/funds/atheneos-ventures) — Series A
- Hercules Bioventures — Series A, Series B
- AshHill Biomedical Investments — Series A
- CDIB Capital Group (https://capitalatlas.ai/funds/cdib-capital-group) — Series B
- Amkey Ventures (https://capitalatlas.ai/funds/amkey-ventures) — Series B
- iD SoftCapital (https://capitalatlas.ai/funds/id-softcapital) — Series B
- Capital TEN II — Series B